Ovarian Endometrioid Adenocarcinoma Recruiting Phase 2 / 3 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0028505 (Ovarian Endometrioid Adenocarcinoma)Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02502266Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTreatment